Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Postma

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Neuro-Oncology|November 23, 2013
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal studyF E Froklage, L J Oosterbaan, E M Sizoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2008
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizerJ Sigmond, R J Honeywell, T J Postma, et al.
Clinical Genetics|January 26, 2011
Childhood brain tumours due to germline bi-allelic mismatch repair gene mutationsP C Johannesma, H M van der Klift, N C T van Grieken, et al.
Journal of Neuro-Oncology|July 21, 2014
End of life care in high-grade glioma patients in three European countries: a comparative studyJ A F Koekkoek, L Dirven, J C Reijneveld, et al.
Neurology|November 26, 2009
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomideH J Dubbink, W Taal, R van Marion, et al.
Lancet (London, England)|November 9, 2002
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative studyM Klein, J J Heimans, N K Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2013
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coinP Alberti, E Rossi, D R Cornblath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findingsG Cavaletti, D R Cornblath, I S J Merkies, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2013
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)D Binda, E K Vanhoutte, G Cavaletti, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Neuro-Oncology|November 23, 2013
Central neurotoxicity of standard treatment in patients with newly-diagnosed high-grade glioma: a prospective longitudinal studyF E Froklage, L J Oosterbaan, E M Sizoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2008
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizerJ Sigmond, R J Honeywell, T J Postma, et al.
Clinical Genetics|January 26, 2011
Childhood brain tumours due to germline bi-allelic mismatch repair gene mutationsP C Johannesma, H M van der Klift, N C T van Grieken, et al.
Journal of Neuro-Oncology|July 21, 2014
End of life care in high-grade glioma patients in three European countries: a comparative studyJ A F Koekkoek, L Dirven, J C Reijneveld, et al.
Neurology|November 26, 2009
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomideH J Dubbink, W Taal, R van Marion, et al.
Lancet (London, England)|November 9, 2002
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative studyM Klein, J J Heimans, N K Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2013
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coinP Alberti, E Rossi, D R Cornblath, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 23, 2012
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findingsG Cavaletti, D R Cornblath, I S J Merkies, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2013
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)D Binda, E K Vanhoutte, G Cavaletti, et al.
Pageof 4